R&D News | pharmaphorum

News

Concept of memory loss and brain aging due to dementia and alzheimer's disease as a medical icon with fall trees shaped as a human head losing leaves with 3D illustration elements.

Biogen abandons tau antibody for Alzheimer's after phase 2 m...

Biogen has four other Alzheimer's candidates in its clinical pipeline behind recently-approved Aduhelm, but one of them – anti-tau antibody gosuranemab – has just been canned.

News

CureVac hit hard as its COVID jab fails to make the grade

CureVac has just had a harsh reminder of the perilous nature of drug development, after reporting that its mRNA-based COVID-19 vaccine was just 47% effective in its 40,000-subject phase 3 t

News

Sage/Biogen's zuranolone works in depression, but maybe not ...

Sage Therapeutics and Biogen's antidepressant candidate zuranolone has hit its objectives in a phase 3 trial, but a falloff in efficacy over time has raised concerns about the commercial po

News

Regeneron drug saves lives in severe COVID-19, but it's not ...

People who cannot generate an effective immune response against COVID-19 can be protected with an infusion of Regeneron's antibody therapy REGN-COV, according to new data from the UK RECOVE

News

Biogen's ambitions in gene therapy hit by another failed piv...

When Biogen acquired Nightstar Therapeutics in 2019, it added a pair inherited retinal disorder (IRD) gene therapies that it hoped would accelerate a push into the fast-evolving category. <

News

Novavax unveils phase 3 COVID jab data, but has it missed th...

The top-line phase 3 data for Novavax' COVID-19 vaccine look good, with a 90% overall efficacy rate, but a dip in its share price indicates investors fear it could be too late for the progr

Biogen abandons tau antibody for Alzheimer's after phase 2 m...

CureVac hit hard as its COVID jab fails to make the grade

Sage/Biogen's zuranolone works in depression, but maybe not ...

Regeneron drug saves lives in severe COVID-19, but it's not ...

Biogen's ambitions in gene therapy hit by another failed piv...

Novavax unveils phase 3 COVID jab data, but has it missed th...

UCB buys cell therapy biotech Candid for $2bn upfront

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks